Feb 14, 2013, 02.09 PM | Source: Reuters
Shares in Dr Reddy's Laboratories fall 2.1 percent on worries the drug maker will post lower-than-expected October-December earnings, due later in the day
Margins are also expected to see significant erosion, several dealers add.
Dr Reddy's could miss consensus earnings per share (EPS) estimates by 6 percent in the October-December quarter, according to Thomson Reuters StarMine SmartEstimate data, which measures the forecasts from top-ranked analysts against wider forecasts. * StarMine SmartEstimate suggests EPS for the quarter ending December at Rs 26.03 compared with mean estimate of Rs 27.89.
Canadian drug regulator Health Canada may soon all
Net Sales are expected to increase by 2.9 percent
Domestic pharmaceutical companies are likely to re
The drug, a therapeutic equivalent generic version
Dr Reddy's Laboratories has launched Aripiprazole